<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28461" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Birdshot Retinopathy</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bergstrom</surname>
            <given-names>Reece</given-names>
          </name>
          <aff>Doctor's Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Czyz</surname>
            <given-names>Craig N.</given-names>
          </name>
          <aff>Ohio University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Reece Bergstrom declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Craig Czyz declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>8</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28461.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Birdshot chorioretinopathy (BCR) is an unusual form of chronic, bilateral, posterior uveitis with a distinguishing clinical phenotype, and a strong association with HLA-A29. This disease predominantly affects middle-aged individuals and more often affects females than males. Early in the course of this disease, patients may present with mild symptoms delaying treatment that can often result in permanent visual dysfunction. The disease is permanent, chronic, and progressive resulting in irreversible ocular damage. This activity will help the clinician gain a deeper understanding of this disease, its diagnosis, and treatment.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the etiology of birdshot chorioretinopathy.</p></list-item><list-item><p>Describe the appropriate evaluation of patients with suspected birdshot chorioretinopathy.</p></list-item><list-item><p>Review the treatment and management options available for birdshot chorioretinopathy.</p></list-item><list-item><p>Outline interprofessional team strategies for improving care coordination and communication to advance birdshot chorioretinopathy and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28461&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28461">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28461.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Birdshot chorioretinopathy (BCR) is a form of chronic, bilateral, posterior uveitis with a distinguishing clinical phenotype, and a strong association with HLA-A29. This disease predominantly affects individuals of middle-age and more often affects females than males.<xref ref-type="bibr" rid="article-28461.r1">[1]</xref> Early in the course of this disease, patients may present with mild symptoms delaying treatment that can often result in permanent vision changes. This disease is permanent, chronic, and progressive resulting in irreversible ocular damage.</p>
        <p>Historically, the first recognition of BCR as a distinct entity was the description by Franceschetti and Babel in 1949 of &#x0201c;candle wax spot chorioretinopathy&#x0201d; in which they reported a 65-year-old woman with discrete depigmented lesions<xref ref-type="bibr" rid="article-28461.r2">[2]</xref>The first use of the term &#x0201c;birdshot retinochoroidopathy&#x0201d; was in 1980 when Ryan and Maumenee discussed 13 patients with a particular syndrome characterized by a white, painless eye with minimal anterior segment inflammation, but with vitritis, retinal vascular leakage, and cream-colored spots at the level of the retinal pigment epithelium (RPE) or deeper retinal layers. The condition was further explored and defined by Gass and others. Since the recognition of BCR, physicians have improved treatment options and outcomes. A major breakthrough was recognizing the immunogenicity of the disease and pathogenesis.</p>
      </sec>
      <sec id="article-28461.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>The etiology of this condition remains unclear, but it is thought to be related to an autoimmune disease. It may be linked to HLA-A29 due to the presence of this marker in an overwhelming percentage of cases, but triggers for the autoimmune disease&#x000a0;remain unclear.</p>
      </sec>
      <sec id="article-28461.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Birdshot chorioretinopathy is an unusual cause of ocular inflammation, and obtaining reliable incidence and prevalence data is difficult due to the rarity of the disease. Studies from Europe and the United States report that BCR accounts for between 0.5% and 1.5% of the uveitis cases seen in specialist uveitis practices.<xref ref-type="bibr" rid="article-28461.r3">[3]</xref><xref ref-type="bibr" rid="article-28461.r4">[4]</xref> BCR is predominantly seen in the middle-aged, and some reports appear to be more common in females. In a systematic review from 2005, Shah et al. reported a mean age of disease onset of 53.0&#x000a0;years (512 patients), and a 54.1&#x000a0;% female preponderance (522 patients).<xref ref-type="bibr" rid="article-28461.r5">[5]</xref> Birdshot chorioretinopathy is most prevalent in White populations, is most commonly diagnosed in people of Northern European ancestry, with only the occasional case report of BCR in Latino-Hispanic, African-American, and Japanese people.<xref ref-type="bibr" rid="article-28461.r6">[6]</xref> The ethnic distribution is relevant to HLA-A29. HLA-A29 subtypes can be observed in many patients, with each subtype having a different prevalence.<xref ref-type="bibr" rid="article-28461.r7">[7]</xref></p>
      </sec>
      <sec id="article-28461.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Recent research has demonstrated that the HLA-A29 gene itself is central to the pathogenesis of the disease.<xref ref-type="bibr" rid="article-28461.r8">[8]</xref><xref ref-type="bibr" rid="article-28461.r9">[9]</xref><xref ref-type="bibr" rid="article-28461.r10">[10]</xref><xref ref-type="bibr" rid="article-28461.r11">[11]</xref>&#x000a0;It is thought that the enzyme ERAP2 may contribute to the genetic mutation.<xref ref-type="bibr" rid="article-28461.r11">[11]</xref>&#x000a0;This enzyme is thought to be part of antigen processing for presentation by class I MHC molecule.<xref ref-type="bibr" rid="article-28461.r12">[12]</xref>&#x000a0;This has been recognized in a number of other conditions, such as Crohn disease and psoriasis. There is strong evidence of selective antigen processing by ERAP2 with HLA-A29 enabling a unique immunogenic signal leading to BCR.<xref ref-type="bibr" rid="article-28461.r10">[10]</xref>&#x000a0;There is continuing debate as to whether BCR is primarily a disease of the choroid or the retina. The indistinct appearance of the lesions, lack of associated RPE pigmentary changes, and the angiographic features of the lesions suggest these lesions are located in the deep choroidal stroma and are associated with the choroidal veins. It is important to recognize that the retinal and choroidal changes are not necessarily concordant and that this reflects our ability to monitor the disease and may reflect different aspects of its pathogenesis.</p>
      </sec>
      <sec id="article-28461.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Multiple foci of lymphocytes are at various levels of the choroid, prelaminar optic nerve head, and surrounding retinal blood vessels. This may indicate primary disease of the choroid with secondary involvement of the retina.<xref ref-type="bibr" rid="article-28461.r13">[13]</xref></p>
      </sec>
      <sec id="article-28461.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Early symptoms include floaters, blurred vision, and decreased vision. Later symptoms in the course of the disease include nyctalopia, diminished contrast sensitivity, and decreased color vision. Fundus examination reveals vitreous inflammation associated multiple yellow-white choroiditis spots that are often initially observed inferior to the optic nerve head. These lesions are usually 500 to 1500 micrometers in diameter. The typical "birdshot" appearance and distributions of lesions gives the disease its name. As the disease progresses, the lesions become more confluent and linear around the veins, eventually becoming more atrophic in appearance.</p>
      </sec>
      <sec id="article-28461.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Fluorescein angiography often shows leaking from the retinal vessels and nerve head. Leakage can often produce cystoid macular edema and is thought to be the leading cause of visual loss in patients with BCR. If there is clinical suspicion for BCR, the following can help confirm the diagnosis: HLA-A29, syphilis serology, ACE level in all cases; interferon-gamma release assay and/or a Mantoux test in selected high-risk cases; chest x-ray (looking for evidence of sarcoidosis or TB) in all cases; Indocyanine green angiography (ICG), fluorescein angiography (FA), and electroretinography (ERG) in all cases.</p>
        <p>Over the years, a number of diagnostic criteria have been proposed.&#x000a0;Essential criteria are (1) bilateral disease; (2) three or more characteristic birdshot lesions inferior or nasal to the disk in one eye; (3) low-grade anterior chamber inflammation (no more than 1+ cells in the anterior chamber on the SUN score); (4) low-grade vitreous inflammation (no more than 2+ on the NEI/SUN vitreous haze score). Birdshot lesions are defined as being &#x0201c;cream-colored, irregular or elongated, choroidal lesions with indistinct borders, the long axis of which is radial to the optic disk.&#x0201d;</p>
      </sec>
      <sec id="article-28461.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment is typically managed by steroids and&#x000a0;steroid-sparing immunomodulatory therapy. Steroids can be given either by mouth or directly into the eye by injection or implant. There is increasing use of steroids being placed into the eye to help control the progression of BCR. The use of steroids can cause an elevation of intraocular pressure, and if left untreated, can result in permanent vision loss. When using steroids, it is important to monitor intraocular pressure as this can often be asymptomatic to the patient until permanent vision loss has occurred. Many of the steroid-sparing immunomodulatory therapies currently used have significant side effects, and this should be discussed with the patient in detail. Unfortunately, there is not one regiment of therapy that is effective for all patients, and many combinations may need to be trialed to control the ocular inflammation. The goal of therapy is to find the lowest amount of medication needed to suppress the ocular inflammation. Often, a patient may need to follow with a rheumatologist or nephrologist for testing and management of these immunomodulatory therapies.&#x000a0;With the use of IMTs, visual acuity can remain stable or can improve by 78.6% to 89.3%.<xref ref-type="bibr" rid="article-28461.r14">[14]</xref><xref ref-type="bibr" rid="article-28461.r15">[15]</xref><xref ref-type="bibr" rid="article-28461.r16">[16]</xref><xref ref-type="bibr" rid="article-28461.r17">[17]</xref></p>
      </sec>
      <sec id="article-28461.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>
<bold>Infectious</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Tuberculosis</p>
          </list-item>
          <list-item>
            <p>Syphilis</p>
          </list-item>
          <list-item>
            <p>Ocular histoplasmosis syndrome</p>
          </list-item>
        </list>
        <p>
<bold>Non-infectious</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Sarcoidosis</p>
          </list-item>
          <list-item>
            <p>Vogt-Koyanagi-Harada syndrome</p>
          </list-item>
          <list-item>
            <p>Sympathetic ophthalmia</p>
          </list-item>
          <list-item>
            <p>Acute posterior multifocal placoid pigment epitheliopathy (APMPPE)</p>
          </list-item>
          <list-item>
            <p>Multiple evanescent white dot syndrome (MEWDS)</p>
          </list-item>
          <list-item>
            <p>Multifocal choroiditis and panuveitis (MCP)</p>
          </list-item>
          <list-item>
            <p>Punctate inner choroidopathy (PIC)</p>
          </list-item>
        </list>
        <p>Lymphoma can masquerade as birdshot retinopathy.</p>
      </sec>
      <sec id="article-28461.s11" sec-type="Toxicity and Adverse Effect Management">
        <title>Toxicity and Adverse Effect Management</title>
        <p>This is dependent on the immunosuppressant regiment assigned to each patient and/or if they are an ocular steroid "responder." Depending on the medications chosen, it may require frequent intraocular pressure measurements, liver function tests, complete blood counts, and other&#x000a0;metabolic profiles. Signs of toxicity should prompt the physician to decrease the medication or switch medications altogether.</p>
      </sec>
      <sec id="article-28461.s12" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Birdshot chorioretinopathy is a progressive disease with the potential for significant visual impairment due to anatomical and functional complications.&#x000a0;</p>
      </sec>
      <sec id="article-28461.s13" sec-type="Complications">
        <title>Complications</title>
        <p>Common causes of visual loss in BCR include refractory cystoid macular edema (CME), macular scarring, development of choroidal neovascular membrane, and cellophane maculopathy. Diffuse retinal dysfunction associated with the long duration of the disease is recognized as a statistically significant risk factor for vision loss.</p>
      </sec>
      <sec id="article-28461.s14" sec-type="Consultations">
        <title>Consultations</title>
        <p>Rheumatology and ophthalmology should work in tandem to control this complicated inflammatory disorder.</p>
      </sec>
      <sec id="article-28461.s15" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Birdshot is an eye disease that should be followed by an ophthalmologist. Sudden changes in vision or symptoms should prompt an evaluation by an ophthalmologist. Even if the vision is fine, an eye exam can be needed to detect low levels of inflammation. Discuss plans for care and follow up with a local ophthalmologist.</p>
      </sec>
      <sec id="article-28461.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Care of coordination by&#x000a0;physicians, nurses, and pharmacists will be required. Often multiple physicians will monitor the status of the patient. An ophthalmologist will follow the ocular inflammation and vision while a rheumatologist or nephrologist may be required to assists in the management of complex immunosuppressant therapies. The goal is to safely control the inflammation while using the least amount of medications and preserve vision in our patients.</p>
      </sec>
      <sec id="article-28461.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28461&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28461">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/eye-health/birdshot-retinopathy/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=28461">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28461/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28461">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-28461.s18">
        <fig id="article-28461.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Birdshot retinopathy Contributed by Katherine Humphreys</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Birdshot" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-28461.s19">
        <title>References</title>
        <ref id="article-28461.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Minos</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Barry</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Southworth</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Folkard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>Duker</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Keane</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Denniston</surname>
                <given-names>AK</given-names>
              </name>
            </person-group>
            <article-title>Birdshot chorioretinopathy: current knowledge and new concepts in pathophysiology, diagnosis, monitoring and treatment.</article-title>
            <source>Orphanet J Rare Dis</source>
            <year>2016</year>
            <month>May</month>
            <day>12</day>
            <volume>11</volume>
            <issue>1</issue>
            <fpage>61</fpage>
            <pub-id pub-id-type="pmid">27175923</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28461.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>FRANCESCHETTI</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>BABEL</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Chorioretinitis with "candle spots," a manifestation of Besnier-Boeck disease].</article-title>
            <source>Ophthalmologica</source>
            <year>1949</year>
            <season>Oct-Nov</season>
            <volume>118</volume>
            <issue>4-5</issue>
            <fpage>701</fpage>
            <page-range>701-10</page-range>
            <pub-id pub-id-type="pmid">15401026</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28461.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>The Manchester Uveitis Clinic: The first 3000 patients, 2: Uveitis Manifestations, Complications, Medical and Surgical Management.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>127</fpage>
            <page-range>127-34</page-range>
            <pub-id pub-id-type="pmid">25393634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28461.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>NP</given-names>
              </name>
            </person-group>
            <article-title>The Manchester Uveitis Clinic: the first 3000 patients--epidemiology and casemix.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2015</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>118</fpage>
            <page-range>118-26</page-range>
            <pub-id pub-id-type="pmid">24295124</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28461.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shah</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Levinson</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Goldhardt</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Gordon</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Gonzales</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Heckenlively</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kappel</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Holland</surname>
                <given-names>GN</given-names>
              </name>
            </person-group>
            <article-title>Birdshot chorioretinopathy.</article-title>
            <source>Surv Ophthalmol</source>
            <year>2005</year>
            <season>Nov-Dec</season>
            <volume>50</volume>
            <issue>6</issue>
            <fpage>519</fpage>
            <page-range>519-41</page-range>
            <pub-id pub-id-type="pmid">16263368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28461.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saito</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Yamamoto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mitamura</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>[Birdshot chorioretinopathy--a case report and a case study in Japanese patients].</article-title>
            <source>Nippon Ganka Gakkai Zasshi</source>
            <year>2002</year>
            <month>Apr</month>
            <volume>106</volume>
            <issue>4</issue>
            <fpage>229</fpage>
            <page-range>229-35</page-range>
            <pub-id pub-id-type="pmid">11979983</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28461.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lages</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Skvortsova</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Jeannin</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Gasc</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Herbort</surname>
                <given-names>CP</given-names>
              </name>
            </person-group>
            <article-title>Low-grade "benign" birdshot retinochoroiditis: prevalence and characteristics.</article-title>
            <source>Int Ophthalmol</source>
            <year>2019</year>
            <month>Sep</month>
            <volume>39</volume>
            <issue>9</issue>
            <fpage>2111</fpage>
            <page-range>2111-2120</page-range>
            <pub-id pub-id-type="pmid">30474776</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28461.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Donvito</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Monnet</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tabary</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Delair</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vittier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>R&#x000e9;veil</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Sivaradjam</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Edelson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Philbert</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Br&#x000e9;zin</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Different HLA class IA region complotypes for HLA-A29.2 and -A29.1 antigens, identical in birdshot retinochoroidopathy patients or healthy individuals.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2005</year>
            <month>Sep</month>
            <volume>46</volume>
            <issue>9</issue>
            <fpage>3227</fpage>
            <page-range>3227-32</page-range>
            <pub-id pub-id-type="pmid">16123423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28461.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Donvito</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Monnet</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tabary</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Delair</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vittier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>R&#x000e9;veil</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Chiquet</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Br&#x000e9;zin</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>A new HLA extended haplotype containing the A*2910 allele in birdshot retinochoroidopathy: susceptibility narrowed to the HLA molecule itself.</article-title>
            <source>Invest Ophthalmol Vis Sci</source>
            <year>2010</year>
            <month>May</month>
            <volume>51</volume>
            <issue>5</issue>
            <fpage>2525</fpage>
            <page-range>2525-8</page-range>
            <pub-id pub-id-type="pmid">19959637</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28461.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuiper</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rothova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Boer</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Radstake</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>The immunopathogenesis of birdshot chorioretinopathy; a bird of many feathers.</article-title>
            <source>Prog Retin Eye Res</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>44</volume>
            <fpage>99</fpage>
            <page-range>99-110</page-range>
            <pub-id pub-id-type="pmid">25434765</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28461.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kuiper</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Van Setten</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ripke</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Van 'T Slot</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Mulder</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Missotten</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Baarsma</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Francioli</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Pulit</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>De Kovel</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Ten Dam-Van Loon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Den Hollander</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Huis in het Veld</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hoyng</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Cordero-Coma</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;n</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lloren&#x000e7;</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Arya</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Thomas</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bakker</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Ophoff</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Rothova</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>De Bakker</surname>
                <given-names>PI</given-names>
              </name>
              <name>
                <surname>Mutis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Koeleman</surname>
                <given-names>BP</given-names>
              </name>
            </person-group>
            <article-title>A genome-wide association study identifies a functional ERAP2 haplotype associated with birdshot chorioretinopathy.</article-title>
            <source>Hum Mol Genet</source>
            <year>2014</year>
            <month>Nov</month>
            <day>15</day>
            <volume>23</volume>
            <issue>22</issue>
            <fpage>6081</fpage>
            <page-range>6081-7</page-range>
            <pub-id pub-id-type="pmid">24957906</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28461.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saveanu</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Lindo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Del Val</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lopez</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lepelletier</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Greer</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Schomburg</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Fruci</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Niedermann</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>van Endert</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Concerted peptide trimming by human ERAP1 and ERAP2 aminopeptidase complexes in the endoplasmic reticulum.</article-title>
            <source>Nat Immunol</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>6</volume>
            <issue>7</issue>
            <fpage>689</fpage>
            <page-range>689-97</page-range>
            <pub-id pub-id-type="pmid">15908954</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28461.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gaudio</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Crawford</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>Histopathology of birdshot retinochoroidopathy.</article-title>
            <source>Br J Ophthalmol</source>
            <year>2002</year>
            <month>Dec</month>
            <volume>86</volume>
            <issue>12</issue>
            <fpage>1439</fpage>
            <page-range>1439-41</page-range>
            <pub-id pub-id-type="pmid">12446382</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28461.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kiss</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Letko</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Foster</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>Long-term follow-up of patients with birdshot retinochoroidopathy treated with corticosteroid-sparing systemic immunomodulatory therapy.</article-title>
            <source>Ophthalmology</source>
            <year>2005</year>
            <month>Jun</month>
            <volume>112</volume>
            <issue>6</issue>
            <fpage>1066</fpage>
            <page-range>1066-71</page-range>
            <pub-id pub-id-type="pmid">15936442</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28461.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pohlmann</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Winterhalter</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pleyer</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>[White dot syndromes : Principles, diagnostics, and treatment].</article-title>
            <source>Ophthalmologe</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>116</volume>
            <issue>12</issue>
            <fpage>1235</fpage>
            <page-range>1235-1256</page-range>
            <pub-id pub-id-type="pmid">31748943</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28461.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Acaba-Berrocal</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Lucio-Alvarez</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Mashayekhi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Shields</surname>
                <given-names>CL</given-names>
              </name>
            </person-group>
            <article-title>Birdshot-like Chorioretinopathy Associated With Pembrolizumab Treatment.</article-title>
            <source>JAMA Ophthalmol</source>
            <year>2018</year>
            <month>Oct</month>
            <day>01</day>
            <volume>136</volume>
            <issue>10</issue>
            <fpage>1205</fpage>
            <page-range>1205-1207</page-range>
            <pub-id pub-id-type="pmid">30054605</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28461.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cunningham</surname>
                <given-names>ET</given-names>
              </name>
              <name>
                <surname>Levinson</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Denniston</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Br&#x000e9;zin</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Zierhut</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Birdshot Chorioretinopathy.</article-title>
            <source>Ocul Immunol Inflamm</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>25</volume>
            <issue>5</issue>
            <fpage>589</fpage>
            <page-range>589-593</page-range>
            <pub-id pub-id-type="pmid">29144845</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
